Nanogami

Executive Summary

Nanogami is a German biotechnology company founded in 2020, headquartered in Munich. Leveraging proprietary DNA origami technology, it develops next-generation biochips for high-precision molecular analysis. These biochips enable faster, more efficient, and cheaper detection of biological molecules, targeting applications in research and diagnostics. The DNA origami approach allows for intricate nanostructures that can be functionalized to capture specific molecules with high sensitivity and specificity, offering a potential advantage over traditional biochip technologies. As a private early-stage company with a small team, Nanogami is focused on advancing its technology from concept to prototype and ultimately to commercial products. The company has not yet disclosed total funding or valuation, suggesting it is in the early stages of development, likely before a series A round. Its position in Munich provides access to a strong life sciences ecosystem in Germany. The success of Nanogami hinges on demonstrating the scalability and reliability of its DNA origami biochips, forming strategic partnerships, and navigating regulatory pathways for diagnostic use.

Upcoming Catalysts (preview)

• Q1 2027Proof-of-concept study publication or prototype validation70% success
• Q2 2027Series A funding round or strategic partnership60% success
• Q4 2027First commercial pilot with a research institution40% success